VivoSeq
Infectious Disease

Meningitis

40

Pipeline Programs↗

5

Active Trials↗

21

Companies Involved↗

Meningitis is a moderately active landscape with 40 programs across 21 companies. The most active players are Biogen, Johnson & Johnson, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 11 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

11/100

Mech. Concentration

11/100

Completion Rate

76/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1M

Meitheal

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical4

Sorafenib

Bayer

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Combivir and Efavirenz

University of Oxford

Depocyt

M.D. Anderson Cancer Center

Phase 18

Meropenem

B. Braun Medical Inc.

Gemcitabine

Johnson & Johnson

Melphalan

Apotex Inc.

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Topotecan Hydrochloride

Gynecologic Oncology Group

Phase 213

Aspirin

Bayer

Bevacizumab

Bio-Thera Solutions

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Isoniazid

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Linezolid

Pfizer

Phase 34

Dexamethasone

Aspen Global Incorporated

Rifampicin

Boehringer Ingelheim

Other TB Drugs

Universitas Padjadjaran

Adjuvant Dexamethasone

Universitas Padjadjaran

Approved11

Daptomycin

Baxter Healthcare Corporation

Doripenem

Shionogi

Rifampin

Sanofi

Ciprofloxacin

Bayer

Itraconazole

Sebela Pharmaceuticals Development LLC

Analysis

Modality Breakdown

89%

Small molecule

41 of 46 classified programs — the dominant modality here.

11%ALL OTHERSVaccine49%Monoclonal antibody12%

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed25 · 60%
Terminated6 · 14%
Unknown status4 · 10%
Withdrawn2 · 5%
Not yet recruiting2 · 5%
Recruiting2 · 5%
Other1 · 2%

Clinical Trials

Trial Activity

42 trials

Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis
Recruiting·UUniversity Hospital, Toulouse·N/A·NCT06482463·185 enrolled
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05383742·330 enrolled
Aciclovir Versus Placebo for HSV-2 Meningitis
Not yet recruiting·—·Phase 4·NCT05452928·150 enrolled
Olorofim in Early Coccidioidal Meningitis
Not yet recruiting·—·Phase 2·NCT07385638·12 enrolled
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Enrolling by invitation·—·Phase 1/2·NCT06811025·24 enrolled
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
Completed·OOxford University Clinical Research Unit, Vietnam·Phase 3·NCT03092817·520 enrolled
Melphalan in Patients With Neoplastic Meningitis
Completed·—·Phase 1·NCT00002750·6 enrolled
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
Completed·Pacira Pharmaceuticals, Inc logoPacira Pharmaceuticals, Inc·Phase 4·NCT00029523·100 enrolled
Understanding the Immune Response to Two Different Meningitis Vaccines
Completed·UUniversity of Oxford·Phase 4·NCT01593514·20 enrolled
Ciprofloxacin for the Prevention of Meningococcal Meningitis
Completed·EEpicentre·Phase 4·NCT02724046·300 enrolled
Adjunctive Linezolid for the Treatment of Tuberculous Meningitis
Completed·UUniversity of California, San Francisco·Phase 2·NCT04021121·40 enrolled
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
Completed·—·Phase 1·NCT00674674·22 enrolled
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
Completed·PPublic Health England·Phase 4·NCT02526394·400 enrolled
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
Completed·UUniversitas Padjadjaran·Phase 2/3·NCT02169882·60 enrolled
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00145249·143 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)